Novartis Licenses ECF843 Eye Drops From Lubris (NVS)

Share it with your friends Like

Thanks! Share it with your friends!


Novartis Licenses ECF843 Eye Drops From Lubris (NVS)
“Exercising our option to in-license ECF843, along with our recent acquisition of Encore Medical for the treatment of presbyopia, underscores our commitment to treating
diseases of the front of the eye which impact millions of people worldwide,” said Vasant Narasimhan, Global Head, Drug Development and Chief Medical Officer, Novartis.
Other products used for treating dry eye include Allergan PLC’s (AGN) old drug Restasis, and Shire PLC’s (SHPG) Xiidra (lifitegrast).
ECF843 works as a recombinant human lubricin (rh-Lubricin) protein, and lubricin protein deficiency is observed in dry eye patients.
Novartis AG (NVS) exercised an option to in-license the dry-eye drug ECF843 outside Europe from Lubris LLC.
ECF843 eye drops are used for treating dry eye, a condition that occurs when tears aren’t able to provide adequate moisture to the eye.
In a small Phase 2 study, ECF843 demonstrated the potential to instantly improve dry eye symptoms by increasing lubrication.


Write a comment